These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 10588446)

  • 1. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.
    Mentlein R
    Regul Pept; 1999 Nov; 85(1):9-24. PubMed ID: 10588446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery?
    Scharpé S; De Meester I
    Verh K Acad Geneeskd Belg; 2001; 63(1):5-32; discussion 32-3. PubMed ID: 11284388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.
    Augustyns K; Bal G; Thonus G; Belyaev A; Zhang XM; Bollaert W; Lambeir AM; Durinx C; Goossens F; Haemers A
    Curr Med Chem; 1999 Apr; 6(4):311-27. PubMed ID: 10101215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B; Hughes TE
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.
    Mentlein R
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):443-52. PubMed ID: 19748062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
    Mest HJ; Mentlein R
    Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
    Kieffer TJ; McIntosh CH; Pederson RA
    Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
    Marguet D; Baggio L; Kobayashi T; Bernard AM; Pierres M; Nielsen PF; Ribel U; Watanabe T; Drucker DJ; Wagtmann N
    Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6874-9. PubMed ID: 10823914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
    Anderluh M; Kocic G; Tomovic K; Kocic R; Deljanin-Ilic M; Smelcerovic A
    Pharmacol Ther; 2016 Nov; 167():100-107. PubMed ID: 27484974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection.
    Proost P; De Meester I; Schols D; Struyf S; Lambeir AM; Wuyts A; Opdenakker G; De Clercq E; Scharpé S; Van Damme J
    J Biol Chem; 1998 Mar; 273(13):7222-7. PubMed ID: 9516414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro.
    Lambeir AM; Proost P; Scharpé S; De Meester I
    Biochem Pharmacol; 2002 Dec; 64(12):1753-6. PubMed ID: 12445864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction.
    Proost P; Struyf S; Schols D; Opdenakker G; Sozzani S; Allavena P; Mantovani A; Augustyns K; Bal G; Haemers A; Lambeir AM; Scharpé S; Van Damme J; De Meester I
    J Biol Chem; 1999 Feb; 274(7):3988-93. PubMed ID: 9933589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
    Holst JJ; Deacon CF
    Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
    J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV.
    Mentlein R; Dahms P; Grandt D; Krüger R
    Regul Pept; 1993 Dec; 49(2):133-44. PubMed ID: 7907802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.